



**GLOBAL HEMP GROUP**  
A HEALTHIER FUTURE THROUGH SUSTAINABLE BUSINESS STRATEGIES

**Annual General and Special Meeting  
of Shareholders  
to be held July 28, 2023**

**NOTICE OF MEETING  
AND  
MANAGEMENT INFORMATION CIRCULAR**

**June 21, 2023**



## **NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON FRIDAY, JULY 28, 2023**

**TO:** The Shareholders of Global Hemp Group Inc.

**NOTICE IS HEREBY GIVEN THAT** the Annual and Special meeting (the “**Meeting**”) of the shareholders of Global Hemp Group Inc. (“**GLOBAL HEMP**”, “**GHG**” or the “**Company**”) will be held at 1083 Roosevelt Crescent, North Vancouver, BC V7P 1M4, on Friday, July 28, 2023 at 11:30 A.M. (PDT) for the following purposes:

1. to receive the audited financial statements of the Company for the years ended September 30, 2021 and September 30, 2022 and the corresponding report of the auditor on those statements;
2. To fix the number of directors for the ensuing year at Four (4);
3. To elect the directors of the Company who will serve until the next annual meeting of Shareholders of the Company;
4. To appoint to appoint DMCL, as the auditor of the Company until the next annual meeting and to authorize the directors to fix their remuneration;
5. To consider, and if deemed advisable adopt a resolution in the form contained within the management information circular, approving the consolidation of the common shares on a maximum basis of up to 25:1 of the Corporation until the next meeting of shareholders;
6. To consider and re-approve the Company’s stock option plan (the “**Stock Option Plan**”);
7. To transact such further or other business as may be properly brought before the Meeting or at any continuation of the Meeting following an adjournment or postponement thereof.

The specific details of the foregoing matters to be put before the meeting are set forth in the management information circular accompanying this notice of meeting (the “**Circular**”).

### **Notice-and-Access**

The Company has chosen to deliver the Notice of Meeting of its Shareholders, this Information Circular and form of proxy forming the proxy-related materials (the “**Proxy Materials**”) using Notice-and-Access provisions, which govern the delivery of proxy-related materials to Shareholders utilizing the internet. Notice-and-Access provisions are found in section 9.1.1 of National Instrument 51-102 – *Continuous Disclosure Obligations* (“**NI 51-102**”) for delivery to registered Shareholders and in section 2.7.1 of National Instrument 54-101 – *Communication with Beneficial Owners of Securities of a Reporting Issuer* (“**NI 54-101**”) for delivery to beneficial Shareholders (together, “**Notice-and-Access Provisions**”).

Notice-and-Access Provisions allow the Company to choose to deliver Proxy Materials to Shareholders by posting them on a non-SEDAR website (usually the reporting issuer’s website or the website of their transfer agent), provided that the conditions of NI 51-102 and NI 54-101 are met, rather than by printing and mailing the Proxy Materials.

Use of Notice-and-Access Provisions reduces paper waste and the Company’s printing and mailing costs. Under Notice-and-Access Provisions, the Company must send a Notice-and-Access Notice and form of proxy to each Shareholder, including registered and beneficial Shareholders, indicating that the Proxy Materials have been posted and explaining how a Shareholder can access them or obtain a paper copy of the Proxy Materials, including the Information Circular, from the Company. This Information Circular has been posted in full, together with the Notice of Annual General and Special Meeting, the form of proxy, and the Financial Statements Request Form, on the Company’s website at [www.globalhempgroup.com/investor-information](http://www.globalhempgroup.com/investor-information) and on the System for Electronic Document Analysis and Retrieval (“**SEDAR**”) online at [www.sedar.com](http://www.sedar.com) under the Company’s profile.

The Information Circular contains details of matters to be considered at the Meeting. **Please review the Information Circular before voting.**

### **How to Obtain Paper Copies of the Information Circular**

Shareholders may request additional information relating to Notice-and-Access Provisions or a paper copy of the Information Circular be mailed to them at no cost by contacting the Company's registrar and transfer agent, Odyssey Trust Company, via [www.odysseycontact.com](http://www.odysseycontact.com) or by telephone at 1-888-290-1175 (toll-free within North America) or 1-587-885-0960 (direct from outside North America).

If you request a paper copy of the Proxy Materials, you will not receive a new form of proxy or VIF. Therefore, you should keep the original form sent to you in order to vote your Shares.

To allow adequate time for a Shareholder to receive and review a paper copy of the Information Circular and then to submit their vote by 11:30 a.m. (PDT) on Wednesday, July 26, 2023, a Shareholder requesting a paper copy of the Information Circular as described above, should ensure such request is received by Odyssey Trust Company no later than 5:00 p.m. (Eastern Time) on Tuesday, July 14, 2023. Under Notice and-Access Provisions, Proxy Materials must be available for viewing for one year from the date of posting and a paper copy of the Proxy Materials can be requested at any time during this period. To obtain a paper copy of the Information Circular after the Meeting date, please contact the Company.

The Notice-and-Access Notice is being provided to Shareholders by the Company, along with the applicable voting document: a form of proxy in the case of registered Shareholders, or a VIF in the case of beneficial (non-registered) holders. Shareholders with existing instructions on their account to receive printed materials will receive a printed copy of the Proxy Materials.

The Circular provides additional information relating to the matters to be dealt with at the Meeting and is deemed to form part of this Notice. Also accompanying this Notice and the Circular is a Request for Financial Statements and form of proxy for use at the Meeting. Any adjourned meeting resulting from an adjournment of the Meeting will be held at a time and place to be specified at the Meeting. Only shareholders of record at the close of business on June 13, 2023 will be entitled to receive notice of and vote at the Meeting.

If you are a registered shareholder but do not wish to, or cannot, attend the Meeting in person, you can appoint someone who will attend the Meeting and act as your proxy holder to vote in accordance with your instructions. If you are unable to attend the Meeting in person, please read the accompanying Circular and enclosed proxy (the "**Proxy**") and then complete, sign, date and return the Proxy, together with the power of attorney or other authority, if required, under which it was signed or a notarized certified copy to the Company's registrar and transfer agent, Odyssey Trust Company, #702 - 67 Yonge Street, Toronto, ON M5E 1J8 at least 48 hours (excluding Saturdays, Sundays and holidays) before the time fixed for the Meeting or any adjournment thereof.

Failure to do so may result in your shares not being voted at the Meeting. Unregistered shareholders who received the Proxy through an intermediary must deliver the proxy in accordance with the instructions given by the intermediary.

**DATED** at Vancouver, British Columbia, this 21<sup>st</sup> day of June 2023.

**Global Hemp Group Inc.**

*"Stephen Barnhill Jr."*

---

By: Stephen Barnhill Jr., President & CEO

## INFORMATION CIRCULAR

---

This Management's Information Circular (the "Information Circular") is being furnished in connection with the solicitation of proxies by and on behalf of management for Global Hemp Group Inc. ("GHG" or the "Company") for use at the annual and special meeting of the shareholders of the Company to be held on Friday, July 28, 2023 at 11:30 A.M. PDT at 1083 Roosevelt Crescent, North Vancouver, BC V7P 1M4. The information contained in this Information Circular, unless otherwise indicated, is as of June 21, 2023.

Shareholders or proxy holders may participate in a meeting of shareholders in person or by telephone if all shareholders and proxy holders participating in the meeting are able to communicate with each other. A shareholder or proxy holder who participates in a meeting in such manner is deemed to be present at the meeting and to have agreed to participate in that manner and the meeting is deemed to be held at the location specified herein. Should you wish to attend participate at the meeting via teleconference, please contact the Company for further instructions.

This Information Circular is being mailed by the management of the Company to everyone who was a shareholder of record of the Company on June 13, 2023, which is the date that has been fixed by the directors of the Company as the record date to determine the shareholders who are entitled to receive notice of the Meeting. The solicitation of proxies will be primarily by mail. Certain employees or directors of the Company may also solicit proxies by telephone or in person. The majority of the costs of solicitation will be borne by the Company. No person has been authorized to give any information or to make any representation in connection with the Annual General Meeting other than those contained in this Circular and, if given or made, any such information or representation should be considered not to have been authorized by the Company.

This Circular does not constitute the solicitation of an offer to purchase any securities or the solicitation of a proxy by any person in any jurisdiction in which such solicitation is not authorized or in which the person making such solicitation is not qualified to do so or to any person to whom it is unlawful to make such solicitation.

Information contained in this Circular should not be construed as legal, tax or financial advice and the shareholders of the Company are urged to consult their own professional advisers in connection therewith.

Under the Company's Articles as amended, the quorum for the transaction of business at a meeting of shareholders is two or more shareholders who are present in person, or who are represented by proxy, shareholders who, in the aggregate, hold at least one-twentieth (1/20 or 5%) of the issued shares entitled to be voted at the meeting. If such a quorum is not present in person or by proxy, the Meeting will be rescheduled.

### **Notice-and-Access**

The Company has chosen to deliver the Notice of Meeting of its Shareholders, this Information Circular and form of proxy forming the proxy-related materials (the "**Proxy Materials**") using Notice-and-Access provisions, which govern the delivery of proxy-related materials to Shareholders utilizing the internet. Notice-and-Access provisions are found in section 9.1.1 of National Instrument 51-102 – *Continuous Disclosure Obligations* ("**NI 51-102**") for delivery to registered Shareholders and in section 2.7.1 of National Instrument 54-101 – *Communication with Beneficial Owners of Securities of a Reporting Issuer* ("**NI 54-101**") for delivery to beneficial Shareholders (together, "**Notice-and-Access Provisions**").

Notice-and-Access Provisions allow the Company to choose to deliver Proxy Materials to Shareholders by posting them on a non-SEDAR website (usually the reporting issuer's website or the website of their transfer agent), provided that the conditions of NI 51-102 and NI 54-101 are met, rather than by printing and mailing the Proxy Materials.

Use of Notice-and-Access Provisions reduces paper waste and the Company's printing and mailing costs. Under Notice-and-Access Provisions, the Company must send a Notice-and-Access Notice and form of proxy to each Shareholder, including registered and beneficial Shareholders, indicating that the Proxy Materials have been posted and explaining how a Shareholder can access them or obtain a paper copy of the Proxy Materials, including the Information Circular, from the Company. This Information Circular has been posted in full, together with the Notice of Annual General and Special Meeting, the form of proxy, and the Financial Statements Request Form, on the Company's website at [www.globalhempgroup.com/investor-information](http://www.globalhempgroup.com/investor-information) and on the System for Electronic Document Analysis and Retrieval ("**SEDAR**") online at [www.sedar.com](http://www.sedar.com) under the Company's profile.

The Information Circular contains details of matters to be considered at the Meeting. **Please review the Information Circular before voting.**

### **How to Obtain Paper Copies of the Information Circular**

Shareholders may request additional information relating to Notice-and-Access Provisions or a paper copy of the Information Circular be mailed to them at no cost by contacting the Company's registrar and transfer agent, Odyssey Trust Company, via [www.odysseycontact.com](http://www.odysseycontact.com) or by telephone at 1-888-2901175 (toll-free within North America) or 1-587-885-0960 (direct from outside North America).

If you request a paper copy of the Proxy Materials, you will not receive a new form of proxy or VIF. Therefore, you should keep the original form sent to you in order to vote your Shares.

To allow adequate time for a Shareholder to receive and review a paper copy of the Information Circular and then to submit their vote by 11:30 a.m. (PDT) on Wednesday, July 26, 2023, a Shareholder requesting a paper copy of the Information Circular as described above, should ensure such request is received by Odyssey Trust Company no later than 5:00 p.m. (Eastern Time) on Tuesday, July 14, 2023. Under Notice and-Access Provisions, Proxy Materials must be available for viewing for one year from the date of posting and a paper copy of the Proxy Materials can be requested at any time during this period. To obtain a paper copy of the Information Circular after the Meeting date, please contact the Company.

The Notice-and-Access Notice is being provided to Shareholders by the Company, along with the applicable voting document: a form of proxy in the case of registered Shareholders, or a VIF in the case of beneficial (non-registered) holders. Shareholders with existing instructions on their account to receive printed materials will receive a printed copy of the Proxy Materials.

## **PART 1 – VOTING**

### ***HOW A VOTE IS PASSED***

All matters that will come to a vote at the Meeting, as described in the attached Notice of Meeting, are ordinary resolutions and can be passed by a simple majority – that is, if more than half of the votes that are cast are in favor, then the resolution is approved (an “**ordinary resolution**”) unless the motion requires a special resolution in which case 2/3 of the votes cast will be required (a “**special resolution**”).

### ***WHO CAN VOTE?***

If you are a registered shareholder of the Company as at June 13, 2023, you are entitled to notice of and to attend at the Meeting and cast a vote for each share registered in your name on all resolutions put before the Meeting. If the shares are registered in the name of a corporation, a duly authorized officer of the corporation may attend on its behalf, but documentation indicating the officer's authority should be presented at the Meeting. If you are a registered shareholder but do not wish to, or cannot, attend the Meeting in person you can appoint someone who will attend the Meeting and act as your proxy holder to vote in accordance with your instructions (see “**VOTING BY PROXY**” below). If your shares are registered in the name of a “nominee” (usually a bank, trust company, securities dealer or other financial institution) you should refer to the section entitled “**BENEFICIAL SHAREHOLDERS**”, below.

It is important that your shares be represented at the Meeting regardless of the number of shares you hold. If you will not be attending the Meeting in person, the Company invites you to complete, date, sign and return your form of proxy as soon as possible so that your shares will be represented.

### ***VOTING BY PROXY***

If you do not come to the Meeting, you can still make your votes count by voting over the internet or via the telephone (see proxy for instructions) or by appointing someone who will be there to act as your proxy holder. You can either tell that person how you want to vote or you can let him or her decide for you. You can do this by completing a form of proxy.

## ***WHAT IS A PROXY?***

A form of proxy is a document that authorizes someone to attend the Meeting and cast your votes for you. A form of proxy is enclosed with this Information Circular. You should use it to appoint a proxy holder, although you can also use any other legal form of proxy.

In order to be valid, you must return the completed form of proxy to the Company's transfer agent, Odyssey Trust Company, not later than 48 hours, excluding Saturdays, Sundays and holidays, prior to the time of the Meeting or any adjournment thereof.

## ***APPOINTING A PROXYHOLDER***

You can choose any individual to be your proxy holder. It is not necessary for the person whom you choose to be a shareholder. To make such an appointment, simply fill in the person's name in the blank space provided in the enclosed form of proxy. To vote your shares, your proxy holder must attend the Meeting. If you do not fill a name in the blank space in the enclosed form of proxy, the persons named in the form of proxy will be deemed to be appointed to act as your proxy holder. Such persons are directors and/or officers of the Company (the "Management Proxy holders").

## ***INSTRUCTING YOUR PROXY***

You may indicate on your form of proxy how you wish your proxy holder to vote your shares. To do this, simply mark the appropriate boxes on the form of proxy. If you do this, your proxy holder must vote your shares according to your instructions.

If you do not give any instructions as to how to vote on a particular issue to be decided at the Meeting, your proxy holder can vote your shares as he or she thinks fit.

At the time of printing this Information Circular, the management of the Company is not aware of any other matter to be presented for action at the Meeting. If, however, other matters do properly come before the Meeting, the persons named on the enclosed form of proxy will vote on them in accordance with their best judgment, pursuant to the discretionary authority conferred by the form of proxy with respect to such matters.

If you have appointed the Management Proxy holders as your proxy holder, they will, unless you give instructions to the contrary, vote your shares at the Meeting as follows:

- FOR** the approval of the financial statements for years ended September 30, 2021 and September 30, 2022;
- FOR** the election of the proposed nominees as directors and fix the number at Four (4);
- FOR** the appointment of DMCL, Chartered Professional Accountants as the auditor of the Company;
- FOR** the resolution to approve the consolidation of the common shares on a maximum basis of up to 25:1 of the Corporation until the next meeting of shareholders
- FOR** the resolution to authorize the directors to fix the remuneration to be paid to the auditor;
- FOR** the re-approval of the Stock Option Plan, if thought fit; and
- FOR** any other matters that come before the Meeting.

## ***REVOKING YOUR PROXY IF YOU CHANGE YOUR MIND***

If you want to revoke your proxy after you have delivered it, you can do so at any time before it is used. You may do this by:

- a) attending the Meeting and voting in person;
- b) signing a proxy bearing a later date;
- c) signing a written statement which indicates, clearly, that you want to revoke your proxy and delivering this signed written statement to the Company at #106 – 1169 Mt. Seymour Road, North Vancouver, BC V7H 2Y4; or

- d) any other manner permitted by law.

Your proxy will only be revoked if a revocation is received by 5:00 P.M. (Pacific Standard Time) on the last business day before the day of the Meeting, or any adjournment thereof, or delivered to the person presiding at the Meeting before it (or any adjournment) commences. If you revoke your proxy and do not replace it with another that is deposited with us before the deadline, you can still vote your shares but to do so you must attend the Meeting in person.

Only registered shareholders may revoke a proxy. If your shares are not registered in your own name and you wish to change your vote, you must, at least 7 days before the Meeting, arrange for your nominee to revoke your proxy on your behalf (see below under “**BENEFICIAL SHAREHOLDERS**”).

### ***REGISTERED SHAREHOLDERS***

Registered Shareholders may wish to vote by Proxy whether or not they are able to attend the Meeting in person. Registered Shareholders electing to submit a Proxy may do so by completing, dating and signing the enclosed form of Proxy and returning it to the Company's transfer agent not less than 48 hours (excluding Saturdays and holidays) before the time fixed for the Meeting or any adjournment(s) or postponement(s) of the Meeting.

### ***BENEFICIAL SHAREHOLDERS***

The following information is of significant importance to shareholders who do not hold common shares in their own name. Beneficial Shareholders should note that the only proxies that can be recognized and acted upon at the Meeting are those deposited by registered shareholders (those whose names appear on the records of the Company as the registered holders of common shares) or as set out in the following disclosure.

If common shares are listed in an account statement provided to a shareholder by a broker, then in almost all cases those common shares will not be registered in the shareholder's name on the records of the Company. Such common shares will more likely be registered under the names of the shareholder's broker or an agent of that broker (an “intermediary”). In the United States, the vast majority of such common shares are registered under the name of Cede & Co. as nominee for The Depository Trust Company (which acts as depository for many U.S. brokerage firms and custodian banks), and in Canada, under the name of CDS & Co. (the registration name for The Canadian Depository for Securities Limited, which acts as nominee for many Canadian brokerage firms).

Intermediaries are required to seek voting instructions from Beneficial Shareholders in advance of meetings of shareholders. Every intermediary has its own mailing procedures and provides its own return instructions to clients. There are two kinds of Beneficial owners - those who object to their name being made known to the issuers of securities which they own (called “**OBOs**” for Objecting Beneficial Owners) and those who do not object to the issuers of the securities they own knowing who they are (called “**NOBOs**” for Non-Objecting Beneficial Owners).

The Company is taking advantage of the provisions of National Instrument 54-101 “Communication with Beneficial Owners of Securities of a Reporting Issuer” that permit it to directly deliver proxy-related materials to its NOBOs. As a result, NOBOs can expect to receive a scannable Voting Instruction Form (“**VIF**”). These VIFs are to be completed and returned to Odyssey Trust Company in the envelope provided or by facsimile or voted via internet as described on the VIF itself which contain complete instructions. Odyssey Trust Company will tabulate the results of the VIFs received from NOBOs and will provide appropriate instructions at the Meeting with respect to the shares represented by the VIFs they receive.”

These security holder materials are being sent to both registered and NOBO owners of the securities of the Company. If you are a non-registered owner, and the Company or its agent has sent these materials directly to you, your name, address, and information about your holdings of securities, have been obtained in accordance with applicable securities regulatory requirements from the intermediary holding the securities on your behalf.

By choosing to send these materials to you directly, the Company (and not the intermediary holding securities on your behalf) has assumed responsibility for (i) sending these materials to you, and (ii) executing your proper voting instructions. Please return your voting instructions as specified in your request for voting instructions.

Beneficial Shareholders who are OBOs should follow the instructions of their intermediary carefully to ensure that their common shares are voted at the Meeting. The form of proxy supplied to you by your broker will be similar to

the proxy provided to registered shareholders by the Company. However, its purpose is limited to instructing the intermediary on how to vote your common shares on your behalf. Most brokers now delegate responsibility for obtaining instructions from clients to Broadridge Financial Solutions, Inc. (“**Broadridge**”) in the United States and in Canada. Broadridge mails a VIF in lieu of a proxy provided by the Company.

The VIF will name the same persons as the Company’s Proxy to represent your common shares at the Meeting. You have the right to appoint a person (who need not be a Beneficial Shareholder of the Company), other than any of the persons designated in the VIF, to represent your common shares at the Meeting and that person may be you. To exercise this right, you should insert the name of the desired representative (which may be yourself) in the blank space provided in the VIF. The completed VIF must then be returned to Broadridge by mail or facsimile or given to Broadridge by phone or over the internet, in accordance with Broadridge’s instructions. Broadridge then tabulates the results of all instructions received and provides appropriate instructions respecting the voting of common shares to be represented at the Meeting and the appointment of any shareholder’s representative.

If you receive a VIF from Broadridge, the VIF must be completed and returned to Broadridge, in accordance with its instructions, well in advance of the Meeting in order to have your common shares voted or to have an alternate representative duly appointed to attend and to vote your common shares at the Meeting.

## **PART 2 – VOTING SHARES AND PRINCIPAL HOLDERS THEREOF**

### ***OUTSTANDING CAPITAL SHARES OF THE COMPANY***

The Company has only one class of shares entitled to be voted at the Meeting, namely, common shares. Each shareholder is entitled to one vote per share registered in his or her name. According to the records of the Company’s Transfer Agent as of June 13, 2023 there were 358,293,392 common shares issued and outstanding.

### ***PRINCIPAL HOLDERS OF SHARES***

Only those common shareholders of record on June 13, 2023 will be entitled to vote at the Meeting or any adjournment thereof. To the knowledge of the directors and executive officers of the Company, there is no shareholder that beneficially owns, directly or indirectly, or exercises control or direction over shares carrying more than 10% of the voting rights attached to all outstanding shares of the Company which have the right to vote in all circumstances.

## **PART 3 – THE BUSINESS OF THE MEETING**

### ***PATICULARS OF MATTERS TO BE ACTED UPON***

To the knowledge of the Company’s directors, the only matters to be dealt with at the Meeting are those matters set forth in the accompanying Notice of Meeting relating to:

1. To receive the audited financial statements of the Company for the years ended September 30, 2021 and September 30, 2022 and the corresponding report of the auditor on those statements;
2. To fix the number of directors for the ensuing year at Four (4);
3. To elect the directors of the Company who will serve until the next annual meeting of Shareholders of the Company;
4. To appoint to appoint DMCL, Chartered Professional Accountants as the auditor of the Company until the next annual meeting and to authorize the directors to fix their remuneration;
5. To consider, and if deemed advisable adopt a resolution in the form contained within the management information circular, approving the consolidation of the common shares on a maximum basis of up to 25:1 of the Corporation until the next meeting of shareholders;
6. To consider and re-approve the Company’s stock option plan (the “Stock Option Plan”);



7. To transact such other business as may properly come before the Meeting or any adjournments thereof.

### **1- Financial Statements**

The audited financial statements of the Company for the year ended September 30, 2021 and September 30, 2022 will be placed before you at the Meeting. A copy of these financial statements, together with the auditor's report thereon, and Management's Discussion and Analysis are available on the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com) and on the Company's website [www.globalhempgroup.com/investor-information](http://www.globalhempgroup.com/investor-information). All Shareholders may request a paper copy of the audited consolidated financial statements by contacting Odyssey toll free at 1.888.290.1175 (1.587.885.0960 if outside Canada and the US).

### **2- Election of Directors**

#### **Advance Notice Provisions**

The Articles of the Company include advance notice provisions (the "Advance Notice Provisions"), which include, among other things, a provision that requires advance notice be given to the Company in circumstances where nominations of persons for election to the Board are made by Shareholders. In the case of an annual meeting of Shareholders (including an annual and special meeting), notice to the Company must be made not later than 5:00 p.m. (Pacific Time) on the 30th day before the date of the meeting of Shareholders (or 40th day before the date of the meeting of Shareholders if notice-and-access (as defined in NI 54-101) is used for delivery of proxy related materials); provided, however, if the first public announcement made by the Company of the date of the meeting (the "Notice Date") is less than 50 days before the meeting date, notice by the nominating Shareholder may be given not later than the close of business on the 10th day following the Notice Date. In the case of a special meeting (which is not also an annual meeting) of Shareholders called for any purpose which includes the election of directors to the Board, notice to the Company must be made not later than the close of business on the 15th day following the Notice Date. In addition, the Advance Notice Provisions set forth the information that a Shareholder must include in the notice to the Company and establishes the form in which the Shareholder must submit the notice for that notice to be in proper written form. The Advance Notice Provisions are available for viewing in the Articles of the Company, which have been filed under the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com).

The Company filed the Notice of Meeting and Record Date on SEDAR on May 12, 2023. As at the date hereof, no nominations for directors were received in accordance with the Advance Notice Provisions.

The Company currently has five (5) directors, of which four directors are standing for re-election. The directors of the Company are elected at each annual general meeting and hold office until the next annual meeting, or until their successors are duly elected or appointed in accordance with the Company's Articles or until such director's earlier death, resignation or removal.

The Company does not have an executive committee and is required to have an Audit Committee. Members of the Audit Committee are as set out below.

Management proposes to nominate the persons named under the heading "Nominees for Election" below for election as directors of the Company. This requires the approval of the shareholders of the Company by an ordinary resolution, which approval will be sought at the Meeting.

### **3- Nominees for Election**

The following information relating to the nominees for directors is based partly on the Company's records and partly on information received by the Company from the nominees, it states the name of each person proposed to be nominated by management for election or re-election as a director and their respective principal occupations during the term that each were directors of the Company and their respective number of common shares of the Company beneficially owned by him or her, directly or indirectly, or over which he or she exercises control or direction, as at the date hereof.

While management does not contemplate that the nominees will be unable to serve as directors, if prior to the Meeting a vacancy occurs in this slate of nominees for any reason, the management representative(s) designated in the Proxy solicited in respect of the Meeting shall have the discretionary authority to vote for the election of any other person as director. Proxies received by the directors on which no designation is made will be voted for the nominees for election as directors or any substitute nominee thereof as may be determined by management, if necessary.

The following is a table of information about the nominees:

<b>Name, Municipality of Residence &amp; Position</b>	<b>Principal Occupation, Business or Employment</b>	<b>Director Since</b>	<b>Shares Owned <sup>(1)</sup></b>
<b>Stephen Barnhill Jr.</b> League City, TX, USA Interim President, CEO & Director	Interim President and Chief Executive Officer of the Company; Former Chief Operating Officer of Apollon Formularies, plc from September 28, 2018 to March 19, 2023	Mar 20, 2023	Nil
<b>Veronique Laberge, CPA<sup>(2)</sup></b> Laval, QC, CANADA Director	President and CEO of Véronique Laberge CPA Inc. since April 2018; Chief Financial Officer of NuGen Medical Devices Inc. since March 2023	Feb 10, 2023	Nil
<b>Aurelio Useche, CMA, MBA, CPA<sup>(2)</sup></b> Verdun, QC, CANADA Director	CEO and Director of Relevium Technologies Inc. since December 2016	Feb 10, 2023	Nil
<b>Curt Huber<sup>(2)</sup></b> Burnaby, BC, CANADA Director	Director of the Company	Nov 17, 2014	4,850,000

<sup>(1)</sup> Information as to ownership of shares has been taken from the list of registered shareholders maintained by the Company's transfer agent or has been provided by the individual or obtained from SEDI.

<sup>(2)</sup> Member of the Audit Committee

The following is a brief biography of each of the members of the Board of Directors of the Corporation:

#### **Stephen Barnhill Jr.**

Mr. Barnhill brings 10+ years C-Level experience to GHG. He formerly was the Chief Operating Officer (COO) of Apollon Formularies, plc, a natural biologics drug discovery company publicly traded on the Aquis Exchange in London, UK, where he was responsible for all company operations in Jamaica, the Caribbean and North America.

Stephen is the Co-Founder and Former President of Apollon Formularies, Inc. a US corporation established in 2014. He was instrumental in the international expansion of Apollon Formularies, Inc. to Jamaica in 2015, co-founding Apollon Formularies Jamaica, Ltd with headquarters in the Faculty of Medical Sciences at the University of the West Indies, Mona in Kingston. Apollon Formularies Jamaica, Ltd has a suite of vertical medical cannabis licenses an International Cancer and Chronic Pain Institute (ICCPI) in Kingston operating with a team of licensed medical doctors, Natural Psychedelic Therapeutics, Ltd to treat patients with psilocybin and an international medical tourism facility on the sea in Negril which treats international patients coming to Jamaica for treatment with Apollon's natural biologic products. Mr. Barnhill was also involved in the expansion of Apollon to Europe.

#### **Veronique Laberge**

Ms. Laberge is a chartered professional accountant and holder of the title of auditor. With more than 17 years of experience in professional practice, she is specialized in certification mandates, general accounting and as a consultant for public and private companies.

#### **Aurelio Useche**

Mr. Useche leverages over 20 years of senior management experience including COO, CFO and CEO in several private and publicly traded corporations in manufacturing, mining exploration, consumer goods and entertainment. Mr. Useche is a CPA, CMA and a graduate of the executive MBA program at Queen's University School of Business. Mr. Useche is also a graduate of the Corporate Directors program at the University of Toronto's Rotman School of Business and of the Masters Certificate program in Risk Management program at York University's Schulich School of Business.

#### **Curt Huber**

Mr. Huber is an independent corporate consultant who has been involved in all facets of public companies for more than 35 years. He is an experienced director and senior officer who has been involved in the hemp industry since 2014. In addition, he has represented public companies in many different sectors, including global streaming business,

mining, oil and gas, and technology. He has also provided investor relation services, raised financing in the public markets and built corporate awareness for the companies with which he has been associated.

There is no proposed nominee for election as a director of the Company or of any of its subsidiaries that beneficially owns, directly or indirectly, or exercises control or direction over shares carrying more than 10% of the voting rights attached to all outstanding shares of the Company which have the right to vote in all circumstances.

The Company's management recommends that shareholders vote in favor of the nominees for election as directors. **Unless you give other instructions, the persons named in the enclosed form of proxy intend to vote FOR the election of the four nominees as directors of the Company for the ensuing year.**

- *Corporate Cease Trade Orders or bankruptcy*

To the knowledge of the management of the Company, other than as specified below, no proposed nominee for election as a director of the Company:

- a) As of the date of this Information Circular or has been within 10 years before the date of this Information Circular, other than as specified below, no proposed nominee for election as a director of the Company is, or has been, within ten years before the date of this Circular, a director or executive officer of any company (including the Company) that, while that person was acting in that capacity:

- (i) was subject to a cease trade order, an order similar to a cease trade order, or an order that denied the relevant company access to any exemption under securities legislation, that was in effect for a period of more than 30 consecutive days (an "Order") that was issued while the proposed director was acting in the capacity as a director, chief executive officer or chief financial officer; or

Aurelio Useche, CEO and Director since December 2016

Relevium is subject to an Order, which remain in place due to delayed financial statements. On November 1, 2021, the Company applied for and received a management cease trade order ("MCTO") in respect of the late filing of its annual financial statements for the year ended June 30, 2021, including the related management discussion and analysis, and CEO and CFO certifications. Due to the fact that the audit process is still not complete, the securities regulator imposed a full Order for the Company until its obligations for continued disclosure are met.

- (ii) was subject to an Order that was issued after the proposed director ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer,
- (b) is, at the date of this Information Circular, or has been within 10 years before the date of this Information Circular, a director or executive officer of any company (including the Company) that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets,
- (c) has, within the 10 years before the date of this Information Circular, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of the proposed director, or
- (d) has been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities

regulatory authority or has been subject to any other penalties or sanctions imposed by a court or regulatory body that would be likely to be considered important to a reasonable shareholder in deciding whether to vote for a proposed director.

- *Penalties or Sanctions*

As of the date of this Information Circular, no proposed nominee for election as a director of the Company is, or has been, subject to any penalties or sanctions imposed by a court relating to Canadian securities legislation or by a Canadian securities regulatory authority or has entered into a settlement agreement with a Canadian securities regulatory authority or been subject to any other penalties or sanctions imposed by a court or regulatory body that would likely to be considered important to a reasonable investor making an investment decision.

- *Personal Bankruptcy*

As of the date of this Information Circular, no proposed nominee for election as a director of the Company has, within the ten years before the date of this Information Circular, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency, or become subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, manager or trustee appointed to hold the assets of the proposed director.

*Conflicts of Interest*

The directors of the Company are required by law to act honestly and in good faith with a view to the best interest of the Company and to disclose any interests which they may have in any project or opportunity of the Company. If a Conflict of interest arises at a meeting of the board of directors, any director in a conflict will disclose his interest and abstain from voting on such matter. In determining whether or not the Company will participate in any project or opportunity, that directors will primarily consider the degree of risk to which the Company may be exposed and its financial position at that time.

Except as disclosed in this Information Circular, to the best of the Company's knowledge, there are no known existing or potential conflicts of interest among the Company and its promoters, directors, officers or other members of management as a result of their outside business interests except that certain of the directors, officers, promoters and other members of management may from time to time serve as directors, officers, promoters and members of management of other public companies, and therefore it is possible that a conflict may arise between their duties as a director, officer, promoter or member of management of those other companies.

**4- *Appointment of Auditors***

The Company's management recommends that shareholders vote in favor of the re-appointment of Dale Matheson Carr-Hilton Labonte LLP, Chartered Professional Accountants, as the Company's auditor for the ensuing year and in favor of granting the Board of Directors the authority to determine the remuneration to be paid to the auditor.

**Unless you give other instructions, the persons named in the enclosed form of proxy intend to vote FOR the appointment of DMCL, Chartered Professional Accountants as the auditor of the Company until the close of the next annual meeting and also intend to vote FOR the proposed resolution to authorize the Board of Directors to fix the remuneration to be paid to the auditor.**

**5- *Consolidation of Common Shares***

At the Meeting, shareholders will be asked to approve a special resolution authorizing the Corporation to consider consolidating the common shares of the Corporation up to a maximum of 25 common shares to 1 common share for a period until the next meeting of shareholders (the "**Consolidation**"). The implementation of the Consolidation is conditional upon the Corporation obtaining all necessary regulatory consents.

The consideration of a Consolidation is being sought on the basis that a smaller number of issued and outstanding shares and a higher per unit common share price would provide a more advantageous market environment for the Corporation's business, provide further flexibility for funding and/or for project acquisition purposes.

In accordance with the bylaws of the Company and the Business Corporations Act (*British Columbia*), the Consolidation must be approved by a majority of the votes cast by 66⅔% of the votes cast in respect thereof by shareholders present in person or represented by proxy at the Meeting (the "**Consolidation Resolution**").

Approval of the Consolidation by the shareholders would give the Board authority to implement the Consolidation at any time up until the next annual meeting of shareholders. In addition, notwithstanding approval of the Consolidation by the shareholders, the Board, in its sole discretion, may revoke the Consolidation Resolution and abandon the Consolidation without further approval, action by, or prior notice to shareholders.

The exercise or conversion price and/or the number of common shares issuable under any outstanding convertible securities, including under any outstanding stock options, warrants, rights and any other similar securities will be proportionately adjusted upon the implementation of the Consolidation, in accordance with the terms of such securities, on the same basis as the Consolidation of the common shares.

Prior to making any amendment to effect the Consolidation, the Company shall first be required to obtain any and all applicable regulatory and Canadian Securities Exchange (the “CSE”) approvals.

The text of the Consolidation Resolution to be voted on at the Meeting by the Shareholders is set forth below:

*“BE IT HEREBY RESOLVED as a special resolution of the Company that:*

- 1. The Company is hereby authorized to alter its share structure by consolidating each of the issued and outstanding common shares of the Company by exchanging up to twenty-five (25) common shares of the Company, or such lesser amount as the directors of the Company may determine, into one (1) common share of the Company, provided that in the event that the consolidation would otherwise result in a shareholder holding a fraction of a common share, such fractional share, if less than one-half, shall be rounded down to zero and, if equal to or greater than one-half, shall be rounded up to one and added to the number of common shares which the shareholder is entitled to receive (the “Consolidation”).*
- 2. Any officer or director of the Company is hereby authorized and directed for and on behalf of the Company to execute and deliver, under corporate seal of the Company or otherwise all documents and instruments and to do all such other acts and things as in his or her opinion may be necessary or desirable to give full effect to the above resolutions.*
- 3. Notwithstanding that this resolution has been passed by the shareholders of the Company, the board of directors be and are hereby authorized and empowered, without further approval of the shareholders of the Company, to determine the consolidation ratio or revoke this resolution at any time before the Consolidation becomes effective.”*

**The Board recommends that shareholders vote in favour of the above Consolidation Resolution. In the absence of instructions to the contrary, the enclosed proxy will be voted in favour of the Consolidation Resolution.**

#### **6- Re-Approval of Stock Option Plan**

Management is seeking shareholder approval for the re-approval and ratification of the Stock Option Plan along with the number of shares reserved for issuance under the Stock Option Plan in accordance with and subject to the rules and policies of the Canadian Securities Exchange (the “CSE”).

The Board of Directors of the Company has established an incentive Stock Option reserving a rolling 10% of the issued and outstanding shares of the Company from time to time. The purpose of the Stock Option Plan is to provide incentive to employees, directors, officers, management companies and consultants who provide services to the Company and reduce the cash compensation the Company would otherwise have to pay.

Pursuant to the CSE, within three years after institution and within every three years thereafter, a listed issuer must obtain security holder approval for an evergreen plan (also known as a rolling plan) to continue to grant awards. The Stock Option Plan was last approved by the Shareholders on April 16, 2021.

#### *- Terms of the Stock Option Plan*

A full copy of the Stock Option Plan is available upon request for review by shareholders. Shareholders may also obtain copies of the Stock Option Plan from the Company prior to the meeting on written request. The following is a summary of the material terms of the Stock Option Plan:

- Number of Shares Reserved. The number of common shares which may be issued pursuant to options granted under the Stock Option Plan (including all options granted by the Company prior to the adoption of the Stock Option Plan) shall equal 10% of the issued and outstanding shares of the Company from time to time at the date of grant.
- Maximum Term of Options. The term of any options granted under the Stock Option Plan is fixed by the Board of Directors and may not exceed five (5) years from the date of grant. The options are non-assignable and non-transferable.
- Exercise Price. The exercise price of options granted under the Stock Option Plan is determined by the Board of Directors, provided that it is not less than the price permitted by the CSE, or, if the shares are no longer listed on the CSE, then such other exchange or quotation system on which the shares are listed or quoted for trading.
- Amendment. The terms of an option may not be amended once issued under CSE requirements. If an option is cancelled prior to the expiry date, the Company shall not grant new options to the same person until 30 days have elapsed from the date of cancellation.
- Vesting. Vesting, if any, and other terms and conditions relating to such options shall be determined by the Board of Directors of the Company or senior officer or employee to which such authority is delegated by the Board from time to time and in accordance with the CSE requirements.
- Termination. Any options granted pursuant to the Stock Option Plan will terminate on (i) the earliest of the expiration date (ii) the end of the period of time permitted for exercise of the Option (not to be in excess of six (6) months), to be determined by the Board at the time of the grant after the Optionee ceased to be eligible for options for any reasons other than death, disability or cause (iii) the 30<sup>th</sup> day after the Optionee who is engaged in Investor Relations for the Company ceases to be so employed (iv) the date on which the Optionee ceased to be eligible for options by reason or termination of the Optionee as an employee, consultant or independent contractor of the Company (v) 120 days from the date on with the Optionee ceased to be eligible for options on account of disability (vi) 120 days from the date of death of the Optionee.
- Administration. The Stock Option Plan is administered by the Board of Directors of the Company or senior officer or employee to which such authority is delegated by the Board from time to time.
- Board Discretion. The Stock Option Plan provides that, generally, the number of shares subject to each option, the exercise price, the expiry time, the extent to which such option is exercisable, including vesting schedules, and other terms and conditions relating to such options shall be determined by the Board of Directors of the Company or senior officer or employee to which such authority is delegated by the Board from time to time and in accordance with the CSE requirements.

Shareholders (being a simple majority of the votes cast by the shareholders who are not insiders of the Company or associates of those insiders) will be asked to approve the following resolution:

***“BE IT RESOLVED:***

1. *that the Stock Option Plan be and the same is hereby approved, confirmed and ratified and that the directors of the Company be and are hereby authorized to make such amendments or revisions to the Stock Option Plan from time to time, without further shareholder approval, as may be required by the CSE or any other stock exchange upon which the Company's shares may be listed for trading in order to cause the Stock Option Plan to fully comply with the requirements of the of such exchange and to fully carry out this resolution;*
2. *all options to acquire common shares of the Company previously issued by the Company to directors, officers, employees and consultants of the Company or any subsidiary of the Company and currently outstanding shall be deemed to have been granted and issued under the Stock Option Plan and otherwise be governed by the terms and conditions of the Stock Option Plan, subject to the specific terms and conditions as to exercise price, vesting periods, if any, and expiry dates as are currently applicable to such options; and*

3. *the reservation under the Stock Option Plan of a maximum up to the amount of 10% of the issued shares of the Company on a rolling basis, at the time of granting of the stock option pursuant to the Stock Option Plan be and the same is hereby approved.*”

The Company’s management recommends that shareholders vote in favor of the resolution to ratify and approve the Stock Option Plan. **Unless you give instructions otherwise, the Management Proxy holders intend to vote FOR the approval and ratification of the Stock Option Plan.**

#### **PART 4 – EXECUTIVE AND DIRECTOR COMPENSATION**

The following information, dated as of June 21, 2023, is presented in accordance with National Instrument Form 51-102F6V Statement of Executive Compensation – Venture Issuers (the “**Form**”) of the Company for the financial year ended on September 30, 2022.

All amounts represented in this form are in Canadian dollars unless stated otherwise. For the purposes of this Form, the terms below have the following meaning:

“**company**” includes other types of business organizations such as partnerships, trusts and other unincorporated business entities;

“**compensation securities**” includes stock options, convertible securities, exchangeable securities and similar instruments including stock appreciation rights, deferred share units and restricted stock units granted or issued by the company or one of its subsidiaries for services provided or to be provided, directly or indirectly, to the company or any of its subsidiaries;

“**external management company**” includes a subsidiary, affiliate or associate of the external management company;

“**named executive officer**” or “**NEO**” means each of the following individuals:

- a) each individual who, in respect of the Company, during any part of the most recently completed financial year, served as chief executive officer (“**CEO**”), including an individual performing functions similar to a CEO;
- b) each individual who, in respect of the Company, during any part of the most recently completed financial year, served as chief financial officer (“**CFO**”), including an individual performing functions similar to a CFO;
- c) in respect of the Company and its subsidiaries, the most highly compensated executive officer other than the individuals identified in paragraphs (a) and (b) at the end of the most recently completed financial year whose total compensation was more than \$150,000 for that financial year;
- d) each individual who would be a NEO under paragraph (c) but for the fact that the individual was not an executive officer of the Company, and was not acting in a similar capacity, at the end of that financial year.

“**plan**” includes any plan, contract, authorization, or arrangement, whether or not set out in any formal document, where cash, compensation securities or any other property may be received, whether for one or more persons;

“**underlying securities**” means any securities issuable on conversion, exchange or exercise of compensation securities.

#### ***DIRECTOR & NAMED EXECUTIVE OFFICER COMPENSATION***

- *Oversight and Description of Director and NEO Compensation*

The Company has not, as of yet, generated any income or cash flows and operates with limited financial resources. The Board of Directors (the “**Board**”), through informal discussion without any formal objectives, criteria or analysis, is responsible for determining the final compensation to be granted to the Company’s executive officers and directors to ensure that such arrangements reflect the responsibilities and risks associated with each position. The Board’s compensation philosophy is aimed at attracting and retaining quality and experienced people which is

critical to the success of the Company and may include a "pay-for-performance" element which supports the Company's commitment to delivering strong performance for the Shareholders.

The Board annually reviews the corporate goals and objectives relevant to executive compensation; evaluates each executive officer's performance in light of those goals and objectives and sets the executive officer's compensation level based, in part, on this evaluation. The Board also takes into consideration the Company's overall performance, shareholder returns, the value of similar incentive awards to executive officers at comparable companies and the awards given to executive officers in past years.

The Company has no arrangements, standard or otherwise, under which Directors are compensated for their services in their capacity as Directors or NEO, or for committee participation or involvement in special assignments during the most recently completed financial year or subsequently, up to and including the date of this Form.

During the financial year ended September 30, 2022, the Company had three (3) NEOs and five (5) directors:

Individual	Position
Curt Huber	CEO/President & Director
Rachel Lu	CFO (from May 6, 2022 onwards)
Sebastian Tang	CFO (from May 20, 2020 until May 6, 2022)
Dr. Paul Perrault	Director
Jeff Kilpatrick	Director
Roger Johnson	Director
Michel Lebeuf	Director

- *Director and NEO Compensation Excluding Compensation Securities*

The following table sets out compensation paid to Management and Directors in the past two fiscal years:

Table of Compensation Excluding Compensation Securities							
Name and position	Year Ended Sept 30	Salary, consulting fee, retainer or commission (\$)	Bonus (\$)	Committee or meeting fees (\$)	Value of perquisites (\$)	Value of all other compensation (\$)	Total compensation (\$)
<b>Curt Huber</b> CEO & Director	2022	22,439	Nil	Nil	Nil	Nil	22,439
	2021	100,000	Nil	Nil	Nil	Nil	100,000
<b>Rachel Lu</b> <sup>(1)</sup> CFO	2022	7,000	Nil	Nil	Nil	Nil	7,000
	2021	Nil	Nil	Nil	Nil	Nil	Nil
<b>Sebastian Tang</b> <sup>(2)</sup> CFO	2022	3,300	Nil	Nil	Nil	Nil	3,300
	2021	7,000	Nil	Nil	Nil	Nil	7,000
<b>Michel Lebeuf</b> <sup>(3)</sup> Director	2022	96,307	Nil	Nil	Nil	Nil	96,307
	2021	99,557	Nil	Nil	Nil	Nil	99,557
<b>Paul Perrault</b> Director	2022	Nil	Nil	Nil	Nil	Nil	Nil
	2021	37,750 <sup>(4)</sup>	Nil	Nil	Nil	Nil	37,750
<b>Roger Johnson</b> Director	2022	16,349 <sup>(5)</sup>	Nil	Nil	Nil	Nil	16,349
	2021	18,007 <sup>(5)</sup>	Nil	Nil	Nil	Nil	18,007
<b>Jeff Kilpatrick</b> Director	2022	Nil	Nil	Nil	Nil	Nil	Nil
	2021	11,500	Nil	Nil	Nil	Nil	11,500



- (1) Rachel Lu was appointed Chief Financial Officer effective May 6/22.
- (2) Sebastian Tang was appointed Chief Financial Officer on May 20/20 and resigned as CFO effective May 6/22.
- (3) The Company incurred legal fees to a law firm that the Director was a partner.
- (4) Fees paid or accrued to a corporation controlled by Paul Perrault.
- (5) Fees paid or accrued to companies controlled by Roger Johnson.

In the above, all amounts of compensation were paid to directors or NEOs in their capacity as directors or NEOs of the Company, in their capacity as members of a committee of the board of directors of the Company, or as consultants or experts, during the Company's past two fiscal years.

- *Stock Options and Other Compensation Securities*

The Stock Option Plan is an important part of the Company's incentive strategy for its directors and officers, permitting them to participate in any appreciation of the market value of the Company's shares over a stated period of time, and is intended to reinforce commitment to long-term growth and shareholder value.

The Stock Option Plan of the Company is administered by the Board and provides that stock options may be issued to directors, officers, employees, consultants and other personnel of the Company. The Stock Option Plan also provides that the number of common shares issuable under the plan, may not exceed 10% of the issued and outstanding common shares of the Company at any time. All stock options granted under the Stock Option Plan expire on a date not later than five years after the date of grant of such option, and are exercisable at an exercise price set by the Board in its sole discretion which price may not be less than the Discounted Market Price (as defined in the Option Plan).

Stock options grants may be made periodically to ensure that the number of options granted to any particular officer or director is commensurate with the officer's level of ongoing responsibility within the Company. The Board will evaluate the number of options an officer has been granted, the exercise price of the options and the term remaining on those options when considering further grants.

The following table sets forth details of the value of compensation securities granted to or exercised by a director or NEO of the Company during the financial year ended September 30, 2022:

<b>Compensation Securities</b>							
<b>Name and Position</b>	<b>Type of compensation security</b>	<b>Number of compensation securities, number of underlying securities, and percentage of class<sup>(1)</sup></b>	<b>Date of issue or grant</b>	<b>Issue, conversion or exercise price (\$)</b>	<b>Closing price of security or underlying security on date of grant (\$)</b>	<b>Closing price of security or underlying security at year end (\$)</b>	<b>Expiry date</b>
<b><i>No options or compensation securities were issued to each NEO or Director for the year ended September 30, 2022</i></b>							

- *Exercise of Compensation Securities by Directors and NEOs*

No compensation securities were exercised by NEOs and directors who were not NEOs of the Company during the financial year ended September 30, 2022.

- *Director and NEO Compensation Excluding Compensation Securities*

In the above, all amounts of compensation were paid to directors or NEOs in their capacity as directors or NEOs of the Company, in their capacity as members of a committee of the board of directors of the Company, or as consultants or experts, during the Company's past two fiscal years.

- *Employment, Consulting and Management Agreements*

Unless indicated otherwise herein, management functions of the Company are substantially performed by directors or NEO (or private companies controlled by them, either directly or indirectly) of the Company and not, to any substantial degree, by any other person with whom the Company has contracted.

For the period ending September 30, 2022:

Curt Huber does not have a formal contract but is working as an at-will employee for his role as CEO, who is active in the day-to-day operations of the Company. The directors have authorized compensation of \$10,000 per month for his services, but due to fiscal restraint Mr. Huber was only compensated \$22,439 during the year, and no further salary was accrued for the period.

Paul Perrault has supplied consulting services to the Company to expand its ongoing hemp related business endeavours and has focused on an initiative to combine hemp-based construction with affordable housing to create carbon negative affordable housing in the Victoriaville area, in Quebec. He does not currently have a formal consulting agreement. In this year he was paid \$Nil through his consulting company Service Conseil Perrault Inc. for the above services.

Rachel Lu, the Company's CFO was contracted through Ethos CPA LLC, a company controlled by her, and charges a regular fee for ongoing accounting, financing and tax services and was paid \$7,000 during the period. Ms. Lu was appointed May 6, 2022, and her contract has no termination or change of control provisions.

Sebastian Tang, the Company's CFO until May 6, 2022 had no formal contract for his services as CFO and as such there were no specific termination or change of control provisions. Mr. Tang was paid \$3,300 during the period, through his wholly owned corporation Bookskipper Accounting & Tax Services.

- *Pension Disclosure*

The Company does not have any pension, retirement or deferred compensation plans, including a defined contribution plans.

The Company has not entered into any compensatory plans, contracts or arrangements with any of its officers or directors whereby such officer or director are entitled to receive compensation as a result of the resignation, retirement or any other termination of employment of the officer or director with the Company or from a change in control of the Company or a change in the officer's responsibilities following a change in control.

During the financial year ended September 30, 2021, the Company had two (2) NEOs and five (5) directors:

<b>Individual</b>	<b>Position</b>
Curt Huber	CEO/President & Director
Sebastian Tang	CFO
Dr. Paul Perrault	Director
Jeff Kilpatrick	Director
Roger Johnson	Director
Michel Lebeuf	Director

- *Director and NEO Compensation Excluding Compensation Securities*

The following table sets out compensation paid to Management and Directors in the fiscal year ending September 30, 2021:

<b>Table of Compensation Excluding Compensation Securities</b>							
<b>Name and position</b>	<b>Year Ended Sept 30</b>	<b>Salary, consulting fee, retainer or commission (\$)</b>	<b>Bonus (\$)</b>	<b>Committee or meeting fees (\$)</b>	<b>Value of perquisites (\$)</b>	<b>Value of all other compensation (\$)</b>	<b>Total compensation (\$)</b>
<b>Curt Huber<sup>(1)</sup></b> CEO & Director	2021	100,000	Nil	Nil	Nil	Nil	100,000
	2020	10,000	Nil	Nil	Nil	Nil	10,000
<b>Sebastian Tang<sup>(2)</sup></b> CFO	2021	7,000	Nil	Nil	Nil	Nil	7,000
	2020	6,500	Nil	Nil	Nil	Nil	6,500
<b>Michel Lebeuf<sup>(3)</sup></b> Director	2021	99,557	Nil	Nil	Nil	Nil	99,557
	2020	35,551	Nil	Nil	Nil	Nil	35,551
<b>Paul Perrault</b> Director	2021	37,750 <sup>(4)</sup>	Nil	Nil	Nil	Nil	37,750 <sup>(4)</sup>
	2020	Nil	Nil	Nil	Nil	Nil	Nil
<b>Roger Johnson<sup>(5)</sup></b> Director	2021	18,007 <sup>(6)</sup>	Nil	Nil	Nil	Nil	18,007 <sup>(5)</sup>
	2020	Nil	Nil	Nil	Nil	Nil	Nil
<b>Jeff Kilpatrick</b> Director	2021	11,500	Nil	Nil	Nil	Nil	11,500
	2020	Nil	Nil	Nil	Nil	Nil	Nil

<sup>(1)</sup> Curt Huber resigned as CFO May 20, 2020. Mr. Huber received no compensation for the position of CFO.

<sup>(2)</sup> Sebastian Tang was appointed Chief Financial Officer on May 20, 2020

<sup>(3)</sup> The Company incurred legal fees to a law firm that the Director was a partner.

<sup>(4)</sup> Fees paid or accrued to a corporation controlled by Paul Perrault.

<sup>(5)</sup> Roger Johnson was appointed Director on April 29, 2021.

<sup>(6)</sup> Fees paid or accrued to companies controlled by Roger Johnson.

In the above, all amounts of compensation were paid to directors or NEOs in their capacity as directors or NEOs of the Company, in their capacity as members of a committee of the board of directors of the Company, or as consultants or experts, during the Company's past two fiscal years.

- *Stock Options and Other Compensation Securities*

The Stock Option Plan is an important part of the Company's incentive strategy for its directors and officers, permitting them to participate in any appreciation of the market value of the Company's shares over a stated period of time, and is intended to reinforce commitment to long-term growth and shareholder value.

The Stock Option Plan of the Company is administered by the Board and provides that stock options may be issued to directors, officers, employees, consultants and other personnel of the Company. The Stock Option Plan also provides that the number of common shares issuable under the plan, may not exceed 10% of the issued and outstanding common shares of the Company at any time. All stock options granted under the Stock Option Plan expire on a date not later than five years after the date of grant of such option, and are exercisable at an exercise price set by the Board in its sole discretion which price may not be less than the Discounted Market Price (as defined in the Option Plan).

Stock options grants may be made periodically to ensure that the number of options granted to any particular officer or director is commensurate with the officer's level of ongoing responsibility within the Company. The Board will evaluate the number of options an officer has been granted, the exercise price of the options and the term remaining on those options when considering further grants.

The following table sets forth details of the value of compensation securities granted to or exercised by a director or NEO of the Company during the financial year ended September 30, 2021:

<b>Compensation Securities</b>							
<b>Name and Position</b>	<b>Type of compensation security</b>	<b>Number of compensation securities, number of underlying securities, and percentage of class<sup>(1)</sup></b>	<b>Date of issue or grant</b>	<b>Issue, conversion or exercise price (\$)</b>	<b>Closing price of security or underlying security on date of grant (\$)</b>	<b>Closing price of security or underlying security at year end (\$)</b>	<b>Expiry date</b>
<b>Curt Huber<sup>(3)</sup></b> CEO & Director	Stock Options	4,800,000 Options (20.13%) 4,800,000 underlying common shares (1.56%)	Jan 25/21	\$0.055	\$0.055	\$0.035	Jan 25/26
<b>Sebastian Tang<sup>(4)</sup></b> CFO	Stock Options	200,000 Options (0.84%) 200,000 underlying common shares (0.06%)	Jan 27/21	\$0.06	\$0.06	\$0.035	Jan 27/26
<b>Michel Lebeuf<sup>(5)</sup></b> Director	Stock Options	500,000 Options (2.10%) 500,000 underlying common shares (0.16%)	Jan 25/21	\$0.055	\$0.055	\$0.035	Jan 25/26
<b>Paul Perrault</b> Director	Stock Options	2,000,000 Options (8.39%) 2,000,000 underlying common shares (0.65%)	Jan 27/21	\$0.06	\$0.06	\$0.035	Jan 27/26
<b>Jeff Kilpatrick<sup>(6)</sup></b> Director	Stock Options	300,000 Options (1.26%) 300,000 underlying common shares (0.10%)	Jan 27/21	\$0.06	\$0.06	\$0.035	Jan 27/26

**NOTES:**

- <sup>(1)</sup> Each option entitles the holder to acquire one Common Share upon exercise. All options vest on the date of grant.
- <sup>(2)</sup> The percentage of class is based on the total number of stock options and common shares outstanding as at September 30, 2021, being 23,850,000 stock options outstanding and 307,993,392 common shares issued and outstanding
- <sup>(3)</sup> As at September 30, 2021, Curt Huber, CEO held 950,000 stock options at \$0.06 with an expiry date of August 8, 2024, and 4,800,000 stock options at \$0.055 with an expiry date of January 25, 2026.
- <sup>(4)</sup> As at September 30, 2021, Sebastian Tang, CFO held 150,000 stock options at \$0.16 with an expiry date of September 20, 2023, 100,000 stock options at \$0.06 with an expiry date of August 8, 2024, and 200,000 stock options at \$0.06 with an expiry date of January 27, 2026.
- <sup>(5)</sup> As at September 30, 2021, Paul Perrault, Director held 2,000,000 stock options at \$0.06 with an expiry date of January 27, 2026.
- <sup>(6)</sup> As at September 30, 2021, Jeff Kilpatrick, Director held 200,000 stock options at \$0.05 with an expiry date of September 20, 2022 and 300,000 stock options at \$0.06 with an expiry date of January 27, 2026

- *Exercise of Compensation Securities by Directors and NEOs*

Compensation securities exercised by NEOs and directors who were not NEOs of the Company during the financial year ended September 30, 2021:

<b>Compensation Securities</b>							
<b>Name and Position</b>	<b>Type of compensation security</b>	<b>Number of Underlying Securities Exercised</b>	<b>Exercise Price Per Security (\$)</b>	<b>Date of Exercise</b>	<b>Closing price per Security on Date of Exercise (\$)</b>	<b>Difference Between Exercise Price and Closing Price on the Date of Exercise (\$)</b>	<b>Total Value on Exercise Date (\$)</b>
<b>Michel Lebeuf</b> Director	Stock Options	500,000 common shares	\$0.055	Feb 25/21	\$0.085	\$0.03	\$15,000

- *Director and NEO Compensation Excluding Compensation Securities*

In the above, all amounts of compensation were paid to directors or NEOs in their capacity as directors or NEOs of the Company, in their capacity as members of a committee of the board of directors of the Company, or as consultants or experts, during the Company's past two fiscal years.

- *Employment, Consulting and Management Agreements*

Unless indicated otherwise herein, management functions of the Company are substantially performed by directors or NEO (or private companies controlled by them, either directly or indirectly) of the Company and not, to any substantial degree, by any other person with whom the Company has contracted.

For the period ending September 30, 2021:

Curt Huber does not have a formal contract but is working as an at-will employee who is active in the day-to-day operations of the Company. The directors have authorized compensation of \$10,000 per month for his services. During the period he was compensated \$100,000.

Paul Perrault has supplied consulting services to the Company to expand its ongoing hemp related business endeavours and focused on development of hemp-based building materials, and in particular hemp blocks. He does not have a formal consulting agreement. For the period was paid \$37,750 through his consulting company Service Conseil Perrault Inc. for the above services.

Sebastian Tang, the Company's CFO had no formal contract for his services as CFO. Mr. Tang was paid \$7,000 during the period for his services, through his wholly owned corporation Bookskipper Accounting & Tax Services.

- *Pension Disclosure*

The Company does not have any pension, retirement or deferred compensation plans, including a defined contribution plans.

The Company has not entered into any compensatory plans, contracts or arrangements with any of its officers or directors whereby such officer or director are entitled to receive compensation as a result of the resignation, retirement or any other termination of employment of the officer or director with the Company or from a change in control of the Company or a change in the officer's responsibilities following a change in control.

## ***SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLAN***

The following table sets forth details with respect to compensation plans under which equity securities of the Company are authorized for issuance during the financial year ended September 30, 2022:

Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted-average exercise price of outstanding options	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
	(a)	(b)	(c)
Equity compensation plans approved by security holders	Stock Option Plan 15,650,000	\$0.055	17,919,339
Equity compensation plans not approved by security holders	-	-	-
<b>Total:</b>	<b>15,650,000</b>	<b>\$0.055</b>	<b>17,919,339</b>

Note: At September 30, 2022, there were 335,693,392 shares issued and outstanding. Under the rolling Stock Option Plan GHG is authorized to issue up to 10% of the shares issued and outstanding as stock options.

### **PART 5 – AUDIT COMMITTEE**

National Instrument 52-110 Audit Committees of the Canadian Securities Administrators (“**NI 52-110**”) requires the Company, as a venture issuer, to disclose annually in its Statement certain information concerning the constitution of its audit committee and its relationship with the Company’s external auditor as set forth below.

#### *- Audit Committee’s Charter*

The Board has adopted a charter (the “**Charter**”) for its audit committee (the “**Audit Committee**”) which establishes the Audit Committee’s mandate, organization, responsibilities and duties. The complete Charter is attached as Schedule “**A**” to this Statement.

#### *- Composition of the Audit Committee*

The Audit Committee will be comprised of three (3) directors, Veronique Laberge, Aurelio Useche and Curt Huber. Veronique Laberge and Aurelio Useche are considered “independent” as that term is defined in applicable securities legislation.

All three Audit Committee members have the ability to read and understand financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Company’s financial statements and are therefore considered “financially literate”.

#### *- Relevant Education and Experience*

All of the audit committee members are businesspeople with experience in financial matters; each has an understanding of accounting principles used to prepare financial statements and varied experience as to general application of such accounting principles, as well as the internal controls and procedures necessary for financial reporting, garnered from working in their individual fields of endeavor. Both Veronique Laberge and Aurelio Useche are CPA’s.

Since the commencement of the Company’s most recently completed financial year ended September 30, 2022, the Board has not failed to adopt a recommendation of the audit committee to nominate or compensate an external auditor.

- *Reliance on Certain Exemptions*

Since the commencement of the Company's most recently completed financial year ended September 30, 2022, the Company has not relied on the exemptions contained in sections 2.4 or 8 of NI 52-110. Section 2.4 provides an exemption from the requirement that the audit committee must pre-approve all non-audit services to be provided by the auditor, where the total amount of fees related to the non-audit services are not expected to exceed 5% of the total fees payable to the auditor in the fiscal year in which the non-audit services were provided. Section 8 permits a company to apply to a securities regulatory authority for an exemption from the requirements of NI 52-110, in whole or in part.

- *Pre-approval Policies and Procedures*

The Audit Committee has not adopted specific policies and procedures for the engagement of non-audit services, save for the requirement that all non-audit services to be performed by the Company's external auditor must be pre-approved and monitored by the Audit Committee. Subject to the requirements of NI 52-110, the engagement of non-audit services is considered by the Board, and where applicable the audit committee, on a case-by-case basis.

- *External Audit Service Fees (By Category)*

In the following table, "audit fees" are fees billed by the Company's external auditor for services provided in auditing the Company's annual financial statements for the subject year. "Audit-related fees" are fees not included in audit fees that are billed by the auditor for assurance and related services that are reasonably related to the performance of the audit or review of the Company's financial statements. "Tax fees" are fees billed by the auditor for professional services rendered for tax compliance, tax advice and tax planning. "All other fees" are fees billed by the auditor for products and services not included in the foregoing categories.

The fees paid by the Company to its external auditors for services rendered to the Company in each of the last two fiscal years, by category, are as follows:

<b>Financial Year Ending</b>	<b>Audit Fees</b>	<b>Audit Related Fees</b>	<b>Tax Fees</b>	<b>All Other Fees</b>
September 30, 2022	\$50,000	Nil	Nil	Nil
September 30, 2021	\$55,000	Nil	\$3,000	Nil

- *Exemption*

The Company is relying on the exemption provided by section 6.1 of NI 52-110, which provides that the Company, as a venture issuer, is not required to comply with Part 3 (Composition of the Audit Committee) and Part 5 (Reporting Obligations) of NI 52-110 which requires certain prescribed disclosure about the Audit Committee in the Company's Annual Information Form, if any.

## **PART 6 – CORPORATE GOVERNANCE**

Corporate governance relates to the activities of the Board, the members of which are elected by and are accountable to the shareholders and takes into account the role of the individual members of management who are appointed by the Board and who are charged with the day-to-day management of the Company. The Board and senior management consider good corporate governance to be central to the effective and efficient operation of the Company.

National Policy 58-201 Corporate Governance Guidelines ("NP 58-201") establishes corporate governance guidelines, which apply to all public companies. The Company has reviewed its own corporate governance practices in light of these guidelines. In certain cases, the Company's practices comply with the guidelines; however, the Board considers that some of the guidelines are not suitable for the Company at its current stage of development and therefore these guidelines have not been adopted.

National Instrument 58-101 Disclosure of Corporate Governance Practices ("NI 58-101") requires the Company to disclose annually in its Statement certain information concerning its corporate governance practices. As a "venture

issuer” the Company is required to make such disclosure with reference to the requirements of Form 58- 101F2, which disclosure is set forth below.

- *Board of Directors*

The Board is currently composed of five (5) directors. All four (4) of the proposed nominees for election are currently directors of the Company. NP 58-201 suggests that the board of directors of every listed company should be constituted with a majority of individuals who qualify as “independent” directors under NI 52-110, which provides that a director is independent if he or she has no direct or indirect “material relationship” with the company. “Material relationship” is defined as a relationship which could, in the view of the Company’s board of directors be reasonably expected to interfere with the exercise of a director’s independent judgment.

The Board is responsible for determining whether a director is an independent director. Of the proposed nominee directors, Aurelio Useche, and Veronique Laberge are considered independent directors of the Company, as they have no ongoing interest or material relationship with the Company other than serving as directors. Stephen Barnhill is the Company’s President and CEO, and Curt Huber, the Company’s former CEO is involved in the day-to-day operations of the Company, therefore they are not considered independent.

- *Mandate of the Board of Directors*

The mandate of the Board is to manage or supervise the management of the business and affairs of the Company and to act with a view to the best interests of the Company. In doing so, the Board oversees the management of the Company’s affairs directly and through its committees. In fulfilling its mandate, the Board, among other matters, is responsible for reviewing and approving the Company’s overall business strategies and its annual business plan, reviewing and approving the annual corporate budget and forecast, reviewing and approving significant capital investments outside the approved budget; reviewing major strategic initiatives to ensure that the Company’s proposed actions accord with shareholder objectives; reviewing succession planning; assessing management’s performance against approved business plans and industry standards; reviewing and approving the reports and other disclosure issued to shareholders; ensuring the effective operation of the Board; and safeguarding shareholders’ equity interests through the optimum utilization of the Company’s capital resources.

The Board also takes responsibility for identifying the principal risks of the Company’s business and for ensuring these risks are effectively monitored and mitigated to the extent reasonably practicable. At this stage of the Company’s development, the Board does not believe it is necessary to adopt a written mandate, as sufficient guidance is found in the applicable corporate and securities legislation and regulatory policies. However, as the Company grows, the Board will move to develop a formal written mandate. In keeping with its overall responsibility for the stewardship of the Company, the Board is also responsible for the integrity of the Company’s internal control and management information systems and for the Company’s policies respecting corporate disclosure and communications.

The Board delegates to management, through the Chief Executive Officer and the Chief Financial Officer, responsibility for meeting defined corporate objectives, implementing approved strategic and operating plans, carrying on the Company’s business in the ordinary course, managing the Company’s cash flow, evaluating new business opportunities, recruiting staff and complying with applicable regulatory requirements. The Board also looks to management to furnish recommendations respecting corporate objectives, long-term strategic plans and annual operating plans.

Currently, the positions of President and Chief Executive Officer are combined. However, given the size of the Company’s current operations, the Board believes that the Company is well serviced and the independence of the Board from management is not compromised by the combined role. In addition, the Board has found that the fiduciary duties placed on management by the Company’s governing corporate legislation and common law and the restrictions on an individual director’s participation in decisions of the Board in which the director has an interest under applicable corporate and securities legislation provide the “independent” directors with significant input and leadership in exercising their responsibilities for independent oversight of management. In addition, each member of the Board understands that he is entitled to seek the advice of an independent expert if he reasonably considers it warranted under the circumstances and the “independent” directors have the ability to meet independently of management whenever deemed necessary.



- *Directorships*

As of the date of this Information Circular, the directors and/or officers listed in the table that follows are currently directors of other reporting issuers (or equivalent) in a jurisdiction or a foreign jurisdiction.

<b>Director / Officer</b>	<b>Other Reporting Issuer <sup>(1)</sup></b>
Aurelio Useche	Cryptostar Corp. (TSXV:CSTR)
Curt Huber	EXLA Resources Inc. (OTC: EXLA) / Cabo Verde Capital Corp. (OTC: CAPV)

<sup>(1)</sup> The above information has been provided by the directors and has not been independently verified by the Company.

- *Orientation and Continuing Education*

Orientation and education of new members of the Board is conducted informally by management and the Board. The orientation provides background information on the Company's history, performance and strategic plans.

New directors are briefed on strategic plans, short, medium and long-term corporate objectives, business risks and mitigation strategies, corporate governance guidelines and existing company policies. However, there is no formal orientation for new members of the Board and this is considered appropriate, given the Company's size and current operations.

- *Ethical Business Conduct*

The Board of Directors expects management to operate the business of the Company in a manner that enhances shareholder value and is consistent with the highest level of integrity. Management is expected to execute the Company's business plan and to meet performance goals and objectives.

However, to date, the Board has not adopted a formal written Code of Business Conduct and Ethics. The Board has found that the fiduciary duties placed on individual directors by the Company's governing corporate legislation and the common law, as well as the restrictions placed by applicable corporate and securities legislation on the individual director's participation in decisions of the Board in which the director has an interest, have been sufficient to ensure that the Board operates independently of management and in the best interests of the Company and its shareholders.

In addition, the limited size of the Company's operations and the small number of officers and employees allows the Board to monitor on an ongoing basis the activities of management and to ensure that the highest standard of ethical conduct is maintained. As the Company grows in size and scope, the Board anticipates that it will formulate and implement a formal Code of Business Conduct and Ethics.

- *Nomination and Assessment*

Given its current size and stage of development, the Board has not appointed a nominating committee and these functions are currently performed by the Board as a whole. Nominees are generally the result of recruitment efforts by Board members, including both formal and informal discussions among Board members and the Chief Executive Officer, and proposed directors' credentials are reviewed in advance of a Board meeting with one or more members of the Board prior to the proposed director's nomination.

The Board of Directors will consider the size of the Board of Directors each year when it considers the number of directors to recommend for director nominees. The criteria for selecting new directors shall reflect the requirements of the listing standards of the CSE (or such other exchange or self-regulatory organization on which the Company's shares are listed for trading) with respect to independence and the following factors:

- i) the appropriate size of the Company's Board;
- ii) the needs of the Company with respect to the particular talents and experience of its directors;
- iii) personal and professional integrity of the candidate;
- iv) level of education and/or business experience;

- v) broad-based business acumen;
- vi) the level of understanding of the Company's business and the industry in which it operates and other industries relevant to the Company's business;
- vii) the ability and willingness to commit adequate time to Board and committee matters;
- viii) the fit of the individual's skills and personality with those of other directors and potential directors in building a Board that is effective, collegial and responsive to the needs of the Company; and
- ix) the ability to think strategically and a willingness to share ideas; and diversity of experiences, expertise and background.

- *Committees of the Board of Directors*

At the present time, the Board of the Company has appointed two formal committee, being the Audit Committee, and the Compensation Committee.

The Audit Committee is comprised of Veronique Laberge, Aurelio Useche and Curt Huber. The Audit Committee is primarily responsible for the policies and practices relating to integrity of financial and regulatory reporting of the Company, as well as internal controls to achieve the objectives of safeguarding the Company's assets; reliability of information; and compliance with policies and laws. See Part 5 "AUDIT COMMITTEE" for further information regarding the mandate of the Company's Audit Committee, its specific authority, duties and responsibilities, as well as the Audit Committee Charter.

The Compensation Committee is currently comprised of Veronique Laberge, Aurelio Useche and Paul Perrault. The Compensation Committee is responsible for determining all forms of compensation to be granted to the Company's executive officers and to the directors to ensure such arrangements reflect the responsibilities and risks associated with each position. In addition, any compensation to be paid to executive officers who are also directors must be approved by the disinterested directors thereby providing the independent directors with significant input into compensation decisions.

As the Company grows, and its operations and management structure become more complex, the Board will likely find it appropriate to constitute additional standing committees, such as a Corporate Governance Committee, and Nominating Committee, and to ensure that such committees are governed by written charters and are composed of at least a majority of independent directors.

- *Indebtedness of Directors and Executive Officers*

Since the beginning of the most recently completed financial year ended September 30, 2022 and as at the date of this Information Circular, no director, executive officer or employee or former director, executive officer or employee of the Company, nor any nominee for election as a director of the Company, nor any associate of any such person, was indebted to the Company during the most recently completed financial year ended September 30, 2022 for other than "routine indebtedness", as that term is defined by applicable securities law; nor was any indebtedness to another entity the subject of a guarantee, support agreement, letter of credit or other similar arrangement or understanding provided by the Company.

- *Compensation*

See Part 4 "EXECUTIVE AND DIRECTOR COMPENSATION" above for details of the compensation paid to the Company's Named Executive Officers and a discussion of the Company's philosophy, objectives and processes with respect to executive compensation.

**PART 7 – OTHER INFORMATION**

- *Interest of Informed Persons in Material Transactions*

Other than as disclosed herein, no proposed nominee for election as a director, and no director or officer of the Company who has served in such capacity since the beginning of the last financial year of the Company, and no shareholder holding of record or beneficially, directly or indirectly, more than 10% of the Company's outstanding common shares, and none of the respective associates or affiliates of any of the foregoing, had any interest in any

transaction with the Company or in any proposed transaction since the beginning of the last completed financial year that has materially affected the Company or is likely to do so.

- *Interest of Certain Persons in Matters to be Acted Upon*

None of the directors or executive officers of the Company, no proposed nominee for election as a director of the Company, none of the persons who have been directors or executive officers of the Company since the commencement of the Company's last completed financial year, none of the other insiders of the Company and no associate or affiliate of any of the foregoing persons has any substantial interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in any matter to be acted upon at the Meeting other than the election of the directors, the approval of the Stock Option Plan and the authorization for the granting of stock options thereunder.

- *Management Contracts*

The management functions of the Company are performed by its directors and senior officers and the Company has no management agreements or arrangements under which such management functions are performed by persons other than the directors and senior officers of the Company.

- *Transfer Agent and Registrar*

The Company's designated Transfer Agent is Odyssey Trust Company, whose offices are located at #702 - 67 Yonge Street, Toronto, ON M5E 1J8.

- *Legal Proceedings*

There are no pending legal proceedings to which the Company is or is likely to be a party or which any of its properties or business interests are, or, to the best of knowledge of management of the Company, likely to be subject of.

- *Other Matters*

Management of the Company is not aware of any other matters to come before the Meeting other than as set forth in the Notice of Meeting that accompanies this Information Circular. If any other matter properly comes before the Meeting, it is the intention of the persons named in the enclosed form of proxy to vote the shares represented thereby in accordance with their best judgment on such matter.

- *Other Material Facts*

There are no other material facts other than as disclosed in this Information Circular.

- *Additional Information*

Financial information about the Company is provided in its comparative financial statements and Management's Discussion and Analysis for the year ended September 30, 2022 and September 30, 2021. You may access these documents through the Internet on the Canadian System for Electronic Document Analysis and Retrieval (SEDAR) at [www.sedar.com](http://www.sedar.com).

**DATED** at Vancouver, British Columbia, this 21<sup>st</sup> day of June 2023.

**Global Hemp Group Inc.**

"Stephen Barnhill Jr."

By: Stephen Barnhill Jr., President and CEO

## Schedule – A

### **CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF GLOBAL HEMP GROUP INC. (the “Company”)**

#### **1. Purpose**

- 1.1. The Audit Committee is ultimately responsible for the policies and practices relating to integrity of financial and regulatory reporting, as well as internal controls to achieve the objectives of safeguarding of corporate assets; reliability of information; and compliance with policies and laws. Within this mandate, the Audit Committee’s role is to:
  - (a) support the Board of Directors in meeting its responsibilities to shareholders;
  - (b) enhance the independence of the external auditor;
  - (c) facilitate effective communications between management and the external auditor and provide a link between the external auditor and the Board of Directors;
  - (d) increase the credibility and objectivity of the Company’s financial reports and public disclosure.
- 1.2. The Audit Committee will make recommendations to the Board of Directors regarding items relating to financial and regulatory reporting and the system of internal controls following the execution of the Committee’s responsibilities as described herein.
- 1.3. The Audit Committee will undertake those specific duties and responsibilities listed below and such other duties as the Board of Directors from time to time prescribe.

#### **2. Membership**

- 2.1. Each member of the Audit Committee must be a director of the Company.
- 2.2. The Audit Committee will consist of at least three members, the majority of whom are neither officers nor employees of the Company or any of its affiliates.
- 2.3. The members of the Audit Committee will be appointed annually by and will serve at the discretion of the Board of Directors.

#### **3. Authority**

- 3.1. In addition to all authority required to carry out the duties and responsibilities included in this charter, the Audit Committee has specific authority to:
  - (a) engage, and set and pay the compensation for, independent counsel and other advisors as it determines necessary to carry out its duties and responsibilities;
  - (b) communicate directly with management and any internal auditor, and with the external auditor without management involvement; and
  - (c) approve interim financial statements and interim MD&A on behalf of the Board of Directors.

#### **4. Duties and Responsibilities**

4.1. The duties and responsibilities of the Audit Committee include:

- (a) recommending to the Board of Directors the external auditor to be nominated by the Board of Directors;
- (b) recommending to the Board of Directors the compensation of the external auditor;
- (c) reviewing the external auditor's audit plan, fee schedule and any related services proposals;
- (d) overseeing the work of the external auditor;
- (e) ensuring that the external auditor is in good standing with the Canadian Public Accountability Board and will enquire if there are any sanctions imposed by the CPAB on the external auditor;
- (f) ensuring that the external auditor meets the rotation requirements for partners and staff on the Company's audits;
- (g) reviewing and discussing with management and the external auditor the annual audited financial statements, including discussion of material transactions with related parties, accounting policies, as well as the external auditor's written communications to the Committee and to management;
- (h) reviewing the external auditor's report, audit results and financial statements prior to approval by the Board of Directors;
- (i) reporting on and recommending to the Board of Directors the annual financial statements and the external auditor's report on those financial statements, prior to Board approval and dissemination of financial statements to shareholders and the public;
- (j) reviewing financial statements, MD&A and annual and interim earnings press releases prior to public disclosure of this information;
- (k) ensuring adequate procedures are in place for review of all public disclosure of financial information by the Company, prior to its dissemination to the public;
- (l) overseeing the adequacy of the Company's system of internal accounting controls and internal audit process obtaining from the external auditor summaries and recommendations for improvement of such internal accounting controls;
- (m) ensuring the integrity of disclosure controls and internal controls over financial reporting;
- (n) resolving disputes between management and the external auditor regarding financial reporting;
- (o) establishing procedures for:
  - i. the receipt, retention and treatment of complaints received by the Company from employees and others regarding accounting, internal accounting controls or auditing matters and questionable practices relating thereto; and
  - ii. the confidential, anonymous submission by employees of the Company or concerns regarding questionable accounting or auditing matters.
- (p) reviewing and approving the Company's hiring policies with respect to partners or employees (or former partners or employees) of either a former or the present external auditor;

- (q) pre-approving all non-audit services to be provided to the Company or any subsidiaries by the Company's external auditor; and
  - (r) overseeing compliance with regulatory authority requirements for disclosure of external auditor services and Audit Committee activities.
- 4.2. The Audit Committee will report, at least annually, to the Board regarding the Committee's examinations and recommendations.

## **5. Meetings**

- 5.1. The quorum for a meeting of the Audit Committee is a majority of the members of the Committee who are not officers or employees of the Company or of an affiliate of the Company;
- 5.2. The members of the Audit Committee must elect a chair from among their number and may determine their own procedures;
- 5.3. The Audit Committee may establish its own schedule that it will provide to the Board of Directors in advance;
- 5.4. The external auditor is entitled to receive reasonable notice of every meeting of the Audit Committee and to attend and be heard thereat;
- 5.5. A member of the Audit Committee or the external auditor may call a meeting of the Audit Committee;
- 5.6. The Audit Committee will meet separately with the President and separately with the Chief Financial Officer of the Company at least annually to review the financial affairs of the Company;
- 5.7. The Audit Committee will meet with the external auditor of the Company at least once each year, at such time(s) as it deems appropriate, to review the external auditor's examination and report; and
- 5.8. The chair of the Audit Committee must convene a meeting of the Audit Committee at the request of the external auditor, to consider any matter that the auditor believes should be brought to the attention of the Board of Directors or the shareholders.

## **6. Reports**

The Audit Committee will record its recommendations to the Board in written form which will be incorporated as a part of the minutes of the Board of Directors' meeting at which those recommendations are presented.

## **7. Minutes**

The Audit Committee will maintain written minutes of its meetings, which minutes will be filed with the minutes of the meetings of the Board of Directors.